A Darwinian Approach to Huntington's Disease
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Next-Generation Sequencing for Identifying a Novel/De Novo
Martínez-Hernández et al. BMC Medical Genomics (2019) 12:68 https://doi.org/10.1186/s12920-019-0528-1 CASE REPORT Open Access Next-generation sequencing for identifying a novel/de novo pathogenic variant in a Mexican patient with cystic fibrosis: a case report Angélica Martínez-Hernández1, Julieta Larrosa2, Francisco Barajas-Olmos1, Humberto García-Ortíz1, Elvia C. Mendoza-Caamal3, Cecilia Contreras-Cubas1, Elaheh Mirzaeicheshmeh1, José Luis Lezana4 and Lorena Orozco1* Abstract Background: Mexico is among the countries showing the highest heterogeneity of CFTR variants. However, no de novo variants have previously been reported in Mexican patients with cystic fibrosis (CF). Case presentation: Here, we report the first case of a novel/de novo variant in a Mexican patient with CF. Our patient was an 8-year-old male who had exhibited the clinical onset of CF at one month of age, with steatorrhea, malabsorption, poor weight gain, anemia, and recurrent respiratory tract infections. Complete sequencing of the CFTR gene by next generation sequencing (NGS) revealed two different variants in trans, including the previously reported CF-causing variant c.3266G > A (p.Trp1089*, W1089*), that was inherited from the mother, and the novel/ de novo CFTR variant c.1762G > T (p.Glu588*). Conclusion: Our results demonstrate the efficiency of targeted NGS for making a rapid and precise diagnosis in patients with clinically suspected CF. This method can enable the provision of accurate genetic counselling, and improve our understanding of the molecular basis of genetic diseases. Keywords: Cystic fibrosis, Next generation sequencing, P.Trp1089*, P.Glu588*, Novel/de novo variant Background been detected, with the deletion of phenylalanine at pos- Cystic fibrosis (CF, MIM# 219700) is the most common ition 508 (c.1521_1523delCTT, p.Phe508del, F508del) autosomal recessive disorder among Caucasians. -
Presentation and Care of a Family with Huntington Disease in a Resource
Charles et al. Journal of Clinical Movement Disorders (2017) 4:4 DOI 10.1186/s40734-017-0050-6 RESEARCHARTICLE Open Access Presentation and care of a family with Huntington disease in a resource-limited community Jarmal Charles1†, Lindyann Lessey1†, Jennifer Rooney1†, Ingmar Prokop1, Katherine Yearwood1, Hazel Da Breo1, Patrick Rooney1, Ruth H. Walker2,3 and Andrew K. Sobering1* Abstract Background: In high-income countries patients with Huntington disease (HD) typically present to healthcare providers after developing involuntary movements, or for pre-symptomatic genetic testing if at familial risk. A positive family history is a major guide when considering the decision to perform genetic testing for HD, both in affected and unaffected patients. Management of HD is focused upon control of symptoms, whether motor, cognitive, or psychiatric. There is no clear evidence to date of any disease-modifying agents. Referral of families and caregivers for psychological and social support, whether to HD-focused centers, or through virtual communities, is viewed as an important consequence of diagnosis. The experience of healthcare for such progressive neurodegenerative diseases in low- and middle-income nations is in stark contrast with the standard of care in high-income countries. Methods: An extended family with many members affected with an autosomal dominantly inherited movement disorder came to medical attention when one family member presented following a fall. Apart from one family member who was taking a benzodiazepine for involuntary movements, no other affected family members had sought medical attention. Members of this family live on several resource-limited Caribbean islands. Care of the chronically ill is often the responsibility of the family, and access to specialty care is difficult to obtain, or is unavailable. -
Parkinson's Disease: What You and Your Family Should Know
Parkinson’s Disease: What You and Your Family Should Know Edited by Gale Kittle, RN, MPH Parkinson’s Disease: What You and Your Family Should Know Table of Contents Chapter 1: Parkinson’s Disease: A Basic Understanding .....................................3 Chapter 2: Medical and Surgical Treatment Options ..........................................11 Chapter 3: Staying Well with Parkinson’s Disease ...............................................16 Chapter 4: Taking Charge of Your Health Care .....................................................22 Chapter 5: Accepting and Adapting to PD ..............................................................27 Chapter 6: Special Concerns of Persons with Young Onset Parkinson’s Disease ........................................................31 Glossary ........................................................................................................................36 About the National Parkinson Foundation ................................................................................38 Acknowledgements ....................................................................................................................... 40 Parkinson’s Disease: What You and Your Family Should Know Chapter 1 Parkinson’s Disease’s: A Basic Understanding Parkinson’s disease (PD) is a complex disorder of the brain. Because it is a disease that affects the brain, it is classified as a neurological disorder – neurological means “related to the nerves” – and the doctors who specialize in diseases that affect the -
Prevalence and Classification of Mild Cognitive Impairment in the Cardiovascular Health Study Cognition Study Part 1
ORIGINAL CONTRIBUTION Prevalence and Classification of Mild Cognitive Impairment in the Cardiovascular Health Study Cognition Study Part 1 Oscar L. Lopez, MD; William J. Jagust; Steven T. DeKosky, MD; James T. Becker, PhD; Annette Fitzpatrick, PhD; Corinne Dulberg, PhD; John Breitner, MD; Constantine Lyketsos, MD; Beverly Jones, MD; Claudia Kawas, MD; Michelle Carlson, PhD; Lewis H. Kuller, MD Objective: To examine the prevalence of mild cogni- was classified as either MCI amnestic-type or MCI mul- tive impairment (MCI) and its diagnostic classification tiple cognitive deficits–type. in the Cardiovascular Health Study (CHS) Cognition Study. Results: The overall prevalence of MCI was 19% (465 of 2470 participants); prevalence increased with age from Design: The CHS Cognition Study is an ancillary study 19% in participants younger than 75 years to 29% in those of the CHS that was conducted to determine the pres- older than 85 years. The overall prevalence of MCI at the ence of MCI and dementia in the CHS cohort. Pittsburgh center was 22% (130 of 599 participants); prevalence of the MCI amnesic-type was 6% and of the Setting: Multicenter population study. MCI multiple cognitive deficits–type was 16%. Patients: We examined 3608 participants in the CHS Conclusions: Twenty-two percent of the participants who had undergone detailed neurological, neuropsycho- aged 75 years or older had MCI. Mild cognitive impair- logical, neuroradiological, and psychiatric testing to iden- ment is a heterogenous syndrome, where the MCI am- tify dementia and MCI. nestic-type is less frequent than the MCI multiple cog- nitive deficits–type. Most of the participants with MCI Main Outcome Measures: The prevalence of MCI was had comorbid conditions that may affect their cognitive determined for the whole cohort, and specific subtypes functions. -
Multi-Omics Analysis Defines Core Genomic Alterations in Pheochromocytomas and Paragangliomas
ARTICLE Received 11 Aug 2014 | Accepted 5 Dec 2014 | Published 27 Jan 2015 DOI: 10.1038/ncomms7044 OPEN Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas Luis Jaime Castro-Vega1,2,*, Eric Letouze´3,*, Nelly Burnichon1,2,4,*, Alexandre Buffet1,2,4, Pierre-He´lie Disderot1,2, Emmanuel Khalifa1,2,4,Ce´line Loriot1,2, Nabila Elarouci3, Aure´lie Morin1,2,Me´lanie Menara1,2, Charlotte Lepoutre-Lussey1,2,5,Ce´cile Badoual1,2,6, Mathilde Sibony2,7, Bertrand Dousset2,8,9,10, Rossella Libe´2,9,10,11,12, Franck Zinzindohoue2,13, Pierre Franc¸ois Plouin1,2,5,12,Je´roˆme Bertherat2,9,10,11,12, Laurence Amar1,2,5, Aure´lien de Reynie`s3, Judith Favier1,2,y & Anne-Paule Gimenez-Roqueplo1,2,4,12,y Pheochromocytomas and paragangliomas (PCCs/PGLs) are neural crest-derived tumours with a very strong genetic component. Here we report the first integrated genomic examination of a large collection of PCC/PGL. SNP array analysis reveals distinct copy-number patterns associated with genetic background. Whole-exome sequencing shows a low mutation rate of 0.3 mutations per megabase, with few recurrent somatic mutations in genes not previously associated with PCC/PGL. DNA methylation arrays and miRNA sequencing identify DNA methylation changes and miRNA expression clusters strongly associated with messenger RNA expression profiling. Overexpression of the miRNA cluster 182/96/183 is specific in SDHB-mutated tumours and induces malignant traits, whereas silencing of the imprinted DLK1-MEG3 miRNA cluster appears as a potential driver in a subgroup of sporadic tumours. -
High-Efficiency CRISPR/Cas9 Mutagenesis of the White Gene in the Milkweed Bug Oncopeltus Fasciatus
| INVESTIGATION High-Efficiency CRISPR/Cas9 Mutagenesis of the white Gene in the Milkweed Bug Oncopeltus fasciatus Katie Reding and Leslie Pick1 Department of Entomology, University of Maryland, College Park, Maryland 20742 ORCID IDs: 0000-0003-2067-4232 (K.R.); 0000-0002-4505-5107 (L.P.) ABSTRACT In this manuscript, we report that clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 is highly efficient in the hemipteran Oncopeltus fasciatus. The white gene is well characterized in Drosophila where mutation causes loss of eye pigmentation; white is a reliable marker for transgenesis and other genetic manipulations. Accordingly, white has been targeted in a number of nonmodel insects to establish tools for genetic studies. Here, we generated mutations in the Of-white (Of-w) locus using CRISPR/Cas9. We found that Of-w is required for pigmentation throughout the body of Oncopeltus, not just the ommatidia. High rates of somatic mosaicism were observed in the injected generation, reflecting biallelic mutations, and a high rate of germline mutation was evidenced by the large proportion of heterozygous G1s. However, Of-w mutations are homozygous lethal; G2 homozygotes lacked pigment dispersion throughout the body and did not hatch, precluding the establishment of a stable mutant line. Embryonic and parental RNA interference (RNAi) were subsequently performed to rule out off-target mutations producing the observed phenotype and to evaluate the efficacy of RNAi in ablating gene function compared to a loss-of-function mutation. RNAi knockdowns phe- nocopied Of-w homozygotes, with an unusual accumulation of orange granules observed in unhatched embryos. This is, to our knowledge, the first CRISPR/Cas9-targeted mutation generated in Oncopeltus. -
Capgras Syndrome Subbarayan Dhivagar1, Jasmine Farhana2
REVIEW ARTICLE Capgras Syndrome Subbarayan Dhivagar1, Jasmine Farhana2 ABSTRACT Capgras syndrome is a neuropsychiatric disorder, and it is also known as impostor syndrome. People who experience this syndrome will have an irrational belief that someone they know or recognize has been replaced by an impostor. The Capgras syndrome can affect anyone, but it is more common in females and rare cases in children. There is no prescribed treatment plan for people who are affected with Capgras syndrome, but there is a supportive psychotherapeutic measure to overcome this delusional disorder. Keywords: Impostor delusion, Misidentification syndrome, Prosopagnosia. Pondicherry Journal of Nursing (2020): 10.5005/jp-journals-10084-12151 INTRODUCTION 1,2Department of Mental Health Nursing, Kasturba Gandhi Nursing Capgras syndrome is a type of delusional disorder in which a person College, Sri Balaji Vidyapeeth, Puducherry, India holds a delusion that a friend, parents, spouse, or other close Corresponding Author: Subbarayan Dhivagar , Department of relatives or pet animals has been replaced by an identical impostor. Mental Health Nursing, Kasturba Gandhi Nursing College, Sri Balaji It is otherwise called as Capgras delusion or impostor delusion. Vidyapeeth, Puducherry, India, Phone: +91 8754733698, e-mail: It may be seen along with other psychiatric disorders such as [email protected] schizophrenia, schizotypal, and neuro-related disorders. How to cite this article: Dhivagar S, Farhana J. Capgras Syndrome. Pon J Nurs 2020;13(2):46–48. HISTORICAL VIEW Source of support: Nil It is named after Jean Marie Joseph Capgras (1873–1950). He was a Conflict of interest: None French psychiatrist, who was best known for the Capgras delusion; it was described in 1923 in a study published by him. -
Cfdna Deconvolution Via NIPT of a Pregnant Woman After Bone Marrow
Zhu et al. Human Genomics (2021) 15:14 https://doi.org/10.1186/s40246-021-00311-w PRIMARY RESEARCH Open Access cfDNA deconvolution via NIPT of a pregnant woman after bone marrow transplant and donor egg IVF Jianjiang Zhu1 , Feng Hui2, Xuequn Mao1, Shaoqin Zhang1, Hong Qi1* and Yang Du2* Abstract Cell-free DNA is known to be a mixture of DNA fragments originating from various tissue types and organs of the human body and can be utilized for several clinical applications and potentially more to be created. Non-invasive prenatal testing (NIPT), by high throughput sequencing of cell-free DNA (cfDNA), has been successfully applied in the clinical screening of fetal chromosomal aneuploidies, with more extended coverage under active research. In this study, via a quite unique and rare NIPT sample, who has undergone both bone marrow transplant and donor egg IVF, we investigated the sources of oddness observed in the NIPT result using a combination of molecular genetics and genomic methods and eventually had the case fully resolved. Along the process, we devised a clinically viable process to dissect the sample mixture. Eventually, we used the proposed scheme to evaluate the relatedness of individuals and the demultiplexed sample components following modified population genetics concepts, exemplifying a noninvasive prenatal paternity test prototype. For NIPT specific applicational concern, more thorough and detailed clinical information should therefore be collected prior to cfDNA-based screening procedure like NIPT and systematically reviewed when an abnormal report is obtained to improve genetic counseling and overall patient care. Keywords: NIPT, Target sequencing, Fetal fraction, IVF, Transplant, Prenatal diagnostic Introduction establishment of circulating tumor DNA (ctDNA) in the Cell-free DNA (cfDNA) is known to be a mixture from plasma of cancer patients [4]. -
Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis
Medical Coverage Policy Effective Date ............................................. 7/15/2021 Next Review Date ......................................12/15/2021 Coverage Policy Number .................................. 0514 Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis Table of Contents Related Coverage Resources Overview ........................................................ 2 Genetics Coverage Policy ............................................ 2 Genetic Testing Collateral File Genetic Counseling ...................................... 2 Recurrent Pregnancy Loss: Diagnosis and Treatment Germline Carrier Testing for Familial Infertility Services Disease .......................................................... 3 Preimplantation Genetic Testing of an Embryo........................................................... 4 Preimplantation Genetic Testing (PGT-A) .. 5 Sequencing–Based Non-Invasive Prenatal Testing (NIPT) ............................................... 5 Invasive Prenatal Testing of a Fetus .......... 6 Germline Mutation Reproductive Genetic Testing for Recurrent Pregnancy Loss ...... 6 Germline Mutation Reproductive Genetic Testing for Infertility ..................................... 7 General Background .................................... 8 Genetic Counseling ...................................... 8 Germline Genetic Testing ............................ 8 Carrier Testing for Familial Disease ........... 8 Preimplantation Genetic Testing of an Embryo.......................................................... -
The Genetic Complexity of Prostate Cancer
G C A T T A C G G C A T genes Review The Genetic Complexity of Prostate Cancer Eva Compérat 1,2,3,*, Gabriel Wasinger 3 , André Oszwald 3 , Renate Kain 3 , Geraldine Cancel-Tassin 1 and Olivier Cussenot 1,4 1 CeRePP/GRC5 Predictive Onco-Urology, Sorbonne University, 75020 Paris, France; [email protected] (G.C.-T.); [email protected] (O.C.) 2 Department of Pathology, Hôpital Tenon, Sorbonne University, 75020 Paris, France 3 Department of Pathology, Medical University of Vienna, 1090 Vienna, Austria; [email protected] (G.W.); [email protected] (A.O.); [email protected] (R.K.) 4 Department of Urology, Hôpital Tenon, Sorbonne University, 75020 Paris, France * Correspondence: [email protected]; Tel.: +33-658246024 Received: 28 September 2020; Accepted: 23 November 2020; Published: 25 November 2020 Abstract: Prostate cancer (PCa) is a major concern in public health, with many genetically distinct subsets. Genomic alterations in PCa are extraordinarily complex, and both germline and somatic mutations are of great importance in the development of this tumor. The aim of this review is to provide an overview of genetic changes that can occur in the development of PCa and their role in potential therapeutic approaches. Various pathways and mechanisms proposed to play major roles in PCa are described in detail to provide an overview of current knowledge. Keywords: prostate cancer; germline mutations; somatic mutations; PTEN; TMPRSS2; ERG; androgen receptors 1. Introduction Prostate cancer (PCa) is a major concern in public health, with more than 1.1 million cases worldwide detected every year [1]. -
A Germline Or De Novo Mutation in Two Families with Gaucher Disease: Implications for Recessive Disorders
European Journal of Human Genetics (2013) 21, 115–117 & 2013 Macmillan Publishers Limited All rights reserved 1018-4813/13 www.nature.com/ejhg SHORT REPORT A germline or de novo mutation in two families with Gaucher disease: implications for recessive disorders Hamid Saranjam1, Sameer S Chopra2,3, Harvey Levy3, Barbara K Stubblefield1, Emerson Maniwang1, Ian J Cohen4,5, Hagit Baris4,5, Ellen Sidransky*,1 and Nahid Tayebi1 Gaucher disease (GD) is an autosomal recessive storage disorder that most commonly results from the inheritance of one identifiable mutant glucocerebrosidase (GBA1) allele from each parent. Here, we report two cases of type 2 GD resulting from the inheritance of one identifiable paternal mutant allele and one allele that likely resulted from a maternal germline mutation. Germline mutations or mosiacism are not generally associated with autosomal recessive disorders. The probands from the two unrelated families had the same maternal mutation, leu444pro, that we propose resulted from a de novo maternal germline mutation occurring at this known ‘hotspot’ for mutation. This first report of a germline mutation for a common point mutation leu444pro (c.1448 T4C;p.leu483pro) in GD has significant implications for molecular diagnostics and genetic counseling in recessive disorders. European Journal of Human Genetics (2013) 21, 115–117; doi:10.1038/ejhg.2012.105; published online 20 June 2012 Keywords: acute neuronopathic Gaucher disease; glucocerebrosidase; germline mutation; DNA mutational analysis; molecular diagnostic INTRODUCTION However, in both cases, the second mutant allele, leu444pro, was Gaucher disease (GD), the most common lysosomal storage disorder, not detected in the mother. This prompted us to explore whether the results from the autosomal recessively inherited deficiency of gluco- leu444pro mutation might have resulted from a maternal germline cerebrosidase (GCase, EC 3.2.1.45).1,2 GD is subdivided into three mutation in these families. -
CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma
Published OnlineFirst August 16, 2016; DOI: 10.1158/0008-5472.CAN-16-1272 Cancer Tumor and Stem Cell Biology Research CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma Josephine Walton1,2, Julianna Blagih3, Darren Ennis1, Elaine Leung1, Suzanne Dowson1, Malcolm Farquharson1, Laura A. Tookman4, Clare Orange5, Dimitris Athineos3, Susan Mason3, David Stevenson3, Karen Blyth3, Douglas Strathdee3, Frances R. Balkwill2, Karen Vousden3, Michelle Lockley4, and Iain A. McNeish1,4 Abstract – – There is a need for transplantable murine models of ovarian ating novel ID8 derivatives that harbored single (Trp53 / )or – – – – high-grade serous carcinoma (HGSC) with regard to mutations in double (Trp53 / ;Brca2 / ) suppressor gene deletions. In these the human disease to assist investigations of the relationships mutants, loss of p53 alone was sufficient to increase the growth between tumor genotype, chemotherapy response, and immune rate of orthotopic tumors with significant effects observed on the microenvironment. In addressing this need, we performed whole- immune microenvironment. Specifically, p53 loss increased exome sequencing of ID8, the most widely used transplantable expression of the myeloid attractant CCL2 and promoted the model of ovarian cancer, covering 194,000 exomes at a mean infiltration of immunosuppressive myeloid cell populations into – – – – depth of 400Â with 90% exons sequenced >50Â. We found no primary tumors and their ascites. In Trp53 / ;Brca2 / mutant functional mutations in genes characteristic of HGSC (Trp53, cells, we documented a relative increase in sensitivity to the PARP Brca1, Brca2, Nf1, and Rb1), and p53 remained transcriptionally inhibitor rucaparib and slower orthotopic tumor growth – – active. Homologous recombination in ID8 remained intact in compared with Trp53 / cells, with an appearance of intratumoral þ functional assays.